Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1 2Phase NA 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Melanoma 3Uveal Melanoma 1Neoplasms 1Neoplasm Metastasis 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 900Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × gp100 Melanoma Antigen × Clear all
NCT00960752 2021-08-13

Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist

M.D. Anderson Cancer Center

Phase 2 Completed
47 enrolled 9 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms

NCT00085189 2014-05-22

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

University of Southern California

Phase 2 Completed
42 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT00303836 2013-06-06

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Terminated
58 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡